DK2252581T3 - Kappa-selektiv opioidreceptorantagonist - Google Patents

Kappa-selektiv opioidreceptorantagonist

Info

Publication number
DK2252581T3
DK2252581T3 DK09703808.7T DK09703808T DK2252581T3 DK 2252581 T3 DK2252581 T3 DK 2252581T3 DK 09703808 T DK09703808 T DK 09703808T DK 2252581 T3 DK2252581 T3 DK 2252581T3
Authority
DK
Denmark
Prior art keywords
cape
receptor antagonist
opioid receptor
selective opioid
selective
Prior art date
Application number
DK09703808.7T
Other languages
Danish (da)
English (en)
Inventor
Buezo Nuria Diaz
David Lee Mckinzie
Charles Howard Mitch
Concepcion Pedregal-Tercero
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK2252581T3 publication Critical patent/DK2252581T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK09703808.7T 2008-01-22 2009-01-13 Kappa-selektiv opioidreceptorantagonist DK2252581T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
US3912108P 2008-03-25 2008-03-25
PCT/US2009/030811 WO2009094260A1 (en) 2008-01-22 2009-01-13 Kappa selective opioid receptor antagonist

Publications (1)

Publication Number Publication Date
DK2252581T3 true DK2252581T3 (da) 2012-07-16

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09703808.7T DK2252581T3 (da) 2008-01-22 2009-01-13 Kappa-selektiv opioidreceptorantagonist

Country Status (32)

Country Link
US (2) US7709522B2 (enExample)
EP (1) EP2252581B1 (enExample)
JP (1) JP5345637B2 (enExample)
KR (1) KR101172170B1 (enExample)
CN (1) CN101925576B (enExample)
AR (1) AR070158A1 (enExample)
AU (1) AU2009206653B2 (enExample)
BR (1) BRPI0907382B8 (enExample)
CA (1) CA2713025C (enExample)
CO (1) CO6290644A2 (enExample)
CY (1) CY1113071T1 (enExample)
DK (1) DK2252581T3 (enExample)
DO (1) DOP2010000222A (enExample)
EA (1) EA017484B1 (enExample)
EC (1) ECSP10010365A (enExample)
ES (1) ES2388708T3 (enExample)
HR (1) HRP20120558T1 (enExample)
IL (1) IL206038A (enExample)
JO (1) JO2797B1 (enExample)
MA (1) MA32751B1 (enExample)
MX (1) MX2010007849A (enExample)
MY (1) MY163014A (enExample)
NZ (1) NZ586225A (enExample)
PE (1) PE20091317A1 (enExample)
PL (1) PL2252581T3 (enExample)
PT (1) PT2252581E (enExample)
SI (1) SI2252581T1 (enExample)
TN (1) TN2010000306A1 (enExample)
TW (1) TWI422369B (enExample)
UA (1) UA100715C2 (enExample)
WO (1) WO2009094260A1 (enExample)
ZA (1) ZA201003908B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709522B2 (en) * 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist
EP2240485B1 (en) * 2008-01-22 2014-10-15 Takeda Pharmaceutical Company Limited Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
EP2757881A4 (en) 2011-09-15 2014-11-12 Univ Kansas KAPPA OPIATE RECEPTOR EFFECTORS AND USES THEREOF
US10813925B2 (en) 2011-09-19 2020-10-27 Carmel—Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
WO2013086496A2 (en) 2011-12-09 2013-06-13 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
ES2770978T3 (es) * 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
DK3596069T3 (da) 2017-03-17 2022-08-01 Scripps Research Inst Kappa-opioid-receptor-antagonister og produkter og fremgangsmåder relateret dertil
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
CN114591211B (zh) * 2020-12-04 2025-10-21 广东东阳光药业股份有限公司 一种酰胺化合物的共晶及其制备方法
CN117615757A (zh) * 2021-05-04 2024-02-27 杨森制药公司 用于治疗抑郁症的组合物和方法
WO2022234457A1 (en) 2021-05-04 2022-11-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023131920A1 (en) * 2022-01-10 2023-07-13 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
JP2025503649A (ja) * 2022-01-10 2025-02-04 ヤンセン ファーマシューティカルズ,インコーポレーテッド うつ病の治療のための組成物及び方法
CA3254546A1 (en) * 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
EP4489748A1 (en) * 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
ES2189759T3 (es) * 1999-05-12 2003-07-16 Hoffmann La Roche Derivados de imidazoiacepina.
US20020052365A1 (en) * 2000-10-05 2002-05-02 Mohler Hanns Selective anxiolytic therapeutic agents
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
WO2003082832A2 (en) * 2002-03-28 2003-10-09 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
PT2208727E (pt) 2002-09-19 2012-10-11 Lilly Co Eli Éteres diarílicos como antagonista do receptor opióide
EP1606275B1 (en) 2003-03-07 2008-08-27 Eli Lilly And Company Opioid receptor antagonists
WO2004080968A1 (en) 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
CN1890208A (zh) 2003-12-12 2007-01-03 伊莱利利公司 类鸦片受体拮抗剂
BRPI0417714A (pt) 2003-12-22 2007-03-20 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
JP2007528898A (ja) 2004-03-12 2007-10-18 イーライ リリー アンド カンパニー オピオイド受容体拮抗物質
AU2005222640A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
US7381750B2 (en) 2004-03-12 2008-06-03 Eli Lilly And Company Amino-phenoxymethyl-benzamide opioid receptor antagonists
US7378448B2 (en) 2004-03-15 2008-05-27 Eli Lilly And Company Diphenylether amide derivatives as opioid receptor antagonists
WO2005090303A1 (en) 2004-03-15 2005-09-29 Eli Lilly And Company 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
PL2001456T3 (pl) 2006-04-04 2010-05-31 Emodys Gmbh Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych
US8633175B2 (en) 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
JP2010500372A (ja) 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
MX2009002527A (es) 2006-09-08 2009-03-20 Pfizer Prod Inc Derivados de eter diarilico y usos de los mismos.
US7709522B2 (en) * 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist

Also Published As

Publication number Publication date
TWI422369B (zh) 2014-01-11
CA2713025C (en) 2012-12-04
DOP2010000222A (es) 2015-11-15
EP2252581A1 (en) 2010-11-24
SI2252581T1 (sl) 2012-09-28
KR20100095639A (ko) 2010-08-31
IL206038A0 (en) 2010-11-30
BRPI0907382B1 (pt) 2020-03-10
EA017484B1 (ru) 2012-12-28
NZ586225A (en) 2012-05-25
CY1113071T1 (el) 2016-04-13
PL2252581T3 (pl) 2012-10-31
CO6290644A2 (es) 2011-06-20
US20100197669A1 (en) 2010-08-05
IL206038A (en) 2013-11-28
BRPI0907382A2 (pt) 2015-07-21
CN101925576A (zh) 2010-12-22
JO2797B1 (en) 2014-03-15
WO2009094260A1 (en) 2009-07-30
MY163014A (en) 2017-07-31
MA32751B1 (fr) 2011-11-01
TW200936129A (en) 2009-09-01
CA2713025A1 (en) 2009-07-30
CN101925576B (zh) 2013-02-06
ECSP10010365A (es) 2010-08-31
ZA201003908B (en) 2011-11-30
JP2011524850A (ja) 2011-09-08
BRPI0907382B8 (pt) 2021-05-25
HRP20120558T1 (hr) 2012-10-31
UA100715C2 (ru) 2013-01-25
AR070158A1 (es) 2010-03-17
AU2009206653A1 (en) 2009-07-30
US7709522B2 (en) 2010-05-04
AU2009206653B2 (en) 2013-07-18
PT2252581E (pt) 2012-08-31
TN2010000306A1 (en) 2011-11-11
HK1146822A1 (en) 2011-07-15
ES2388708T3 (es) 2012-10-17
US8173695B2 (en) 2012-05-08
EA201070877A1 (ru) 2010-12-30
MX2010007849A (es) 2010-08-09
KR101172170B1 (ko) 2012-08-07
JP5345637B2 (ja) 2013-11-20
EP2252581B1 (en) 2012-06-20
PE20091317A1 (es) 2009-09-03
US20090186873A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
HUS2200033I1 (hu) CGRP receptor antagonisták
HUS2200025I1 (hu) C5AR antagonisták
LTC2379069I2 (lt) S1p receptoriaus agonisto dozavimas
EP2350060A4 (en) Melanocortin receptor AGONISTS
BRPI0907382A2 (pt) Antagonista de receptor de opioide seletivo capa.
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
BRPI0923512A2 (pt) antagonistas de receptores de ácido lisofosfatídico
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
BRPI0919539A2 (pt) antagonistas de receptor de opioide periférico e empregos dos mesmos
DK2501703T3 (da) Spiropiperidinforbindelser som orl-1-receptorantagonister
BRPI0918760A2 (pt) compostos morfinanos
BRPI0810926A2 (pt) Antagonista de crig
BRPI1016189A2 (pt) compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2
HRP20170246T1 (hr) Režim doziranja za selektivni agonist s1p1-receptora
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
DK2081951T3 (da) Progesteron-receptorantagonister
DK2448963T3 (da) T-celle receptorer
SMT201400113B (it) Nalmefene cloridrato diidrato
DK2009992T3 (da) Il-8 receptor-antagonister
IL208355A0 (en) Heterocyclic copmpounds as adenosine receptor antagonist
DK2799428T3 (da) Glucagon-antagonister
HRP20160950T1 (hr) Polimorfi antagonista mglur5 receptora
BR112012003976A2 (pt) antagonistas de receptor glyt1 carbocíclico